ClinicalTrials.gov record
Completed Phase 3 Interventional

Study Comparing the Safety and Efficacy of Piperacillin/Tazobactam to Cefepime in Patients With Hematologic Malignancy or Lymphoma

ClinicalTrials.gov ID: NCT00044759

Public ClinicalTrials.gov record NCT00044759. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 22, 2026, 11:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Open-Label, Multi-Center, Comparative Study of the Efficacy and Safety of Piperacillin/Tazobactam to Cefepime for the Empiric Treatment of Neutropenic Fever in Patients With a Hematologic Malignancy or Lymphoma

Study identification

NCT ID
NCT00044759
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Enrollment
Not listed

Conditions and interventions

Interventions

  • Piperacillin/Tazobactam (Tazocin) Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Not listed
Primary completion
Not listed
Completion
Dec 31, 2002
Last update posted
Oct 9, 2007

Ends 2003

United States locations

U.S. sites
31
U.S. states
17
U.S. cities
28
Facility City State ZIP Site status
Not listed Little Rock Arkansas 72205
Not listed Los Angeles California 90089
Not listed Denver Colorado 80205
Not listed Gainesville Florida 32610
Not listed North Miami Florida 33169
Not listed Ocala Florida 34474
Not listed St. Petersburg Florida 33705
Not listed Thomasville Georgia 31792
Not listed Chicago Illinois 60611
Not listed Chicago Illinois 60637
Not listed Iowa City Iowa 52242
Not listed Louisville Kentucky 40202
Not listed Camden New Jersey 08103
Not listed Hackensack New Jersey 7601
Not listed Buffalo New York 14263
Not listed New York New York 10021
Not listed Rochester New York 14621
Not listed Rochester New York 14642-8668
Not listed The Bronx New York 10466
Not listed Valhalla New York 10595
Not listed Tulsa Oklahoma 74136
Not listed Philadelphia Pennsylvania 19104
Not listed Philadelphia Pennsylvania 19107
Not listed Sayre Pennsylvania 18840
Not listed Upland Pennsylvania 19013
Not listed West Reading Pennsylvania 19611
Not listed Providence Rhode Island 02908
Not listed Columbia South Carolina 29203
Not listed Houston Texas 77030
Not listed Morgantown West Virginia 26506-9162
Not listed Milwaukee Wisconsin 53226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00044759, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 9, 2007 · Synced Apr 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00044759 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →